Table 3.
SPRINT and HOPE-3 Trial Actual vs Potentially Eligible Patients in US Population
| Characteristic | SPRINT Trial | SPRINT Eligiblea | HOPE-3 Trial | HOPE-3 Eligiblea |
|---|---|---|---|---|
| Age, mean, y | 67.9 | 65.2 (59.0–72.0) | 65.8 | 65.1 (5.0–70.0) |
| Male sex, % | 64.0 | 61.1 (58.1–64.1) | 54.2 | 64.4 (59.6–68.8) |
| SBP, mean, mm Hg | 139.7 | 144.8 (135.3–152.7) | 138.2 | 128.4 (116.0–139.3) |
| DBP, mean, mm Hg | 78.2 | 75.3 (68.0–83.3) | 82.0 | 71.5 (65.3–78.7) |
| BMI, mean | 29.9 | 29.1 (25.1–32.0) | 27.1 | 28.0 (23.5–31.6) |
| Smoker, % | NA | 21.5 (18.8–24.4) | 28.0 | 26.7 (22.3–31.6) |
| GFR, mean, mL/min/1.72 m2 | 71.8 | 77.7 (64.6–89.8) | NA | 79.3 (66.2–91.1) |
| Total cholesterol level, mean, mg/dL | 190.2 | 211.8 (183.0–237.0) | 201.4 | 201.0 (176.0–224.0) |
| HDL-C level, mean, mg/dL | 52.9 | 51.8 (41.0–60.0) | 44.9 | 56.7 (44.0–68.0) |
| Prior CVD, % | 16.7 | 13.5 (10.5–17.3) | NA | NA |
| Framingham risk, % | 20.1 | 24.6 (17.5–29.3) | NA | 16.6 (10.5–20.3) |
| 10-y CVD risk, % | NA | 18.1 (11.1–22.9) | NA | 12.9 (7.4–16.3) |
Abbreviations: BMI, body mass index (calculated as a measure of weight in kilograms divided by square of height in meters); CVD, cardiovascular disease; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HOPE-3, Heart Outcomes Prevention Evaluation–3; NA, not applicable; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial.
SI conversion factors: To convert total cholesterol and HDL-C to millimoles per liter, multiply by 0.0259.
a
Data are presented as percentage (95% CI) of column total, and continuous variables are presented as mean (interquartile range).